Keyphrases
Phase II Study
100%
Ipilimumab
100%
Metastatic Uveal Melanoma
100%
Nivolumab
100%
Overall Survival
50%
Overall Response Rate
50%
Systemic Therapy
25%
Median Overall Survival
25%
Complete Response
25%
Adverse Events
25%
Partial Response
25%
Progression-free Survival
25%
Median Progression-free Survival
25%
4-cycle
25%
Treatment-related Adverse Events
25%
Prior Treatment
25%
Combination Regimen
25%
Maintenance Therapy
25%
Survival Events
25%
Therapy Options
25%
Uveal Melanoma
25%
RECIST 1.1
25%
Combination Immunotherapy
25%
Nivolumab Plus Ipilimumab
25%
Medicine and Dentistry
Arm
100%
Ipilimumab
100%
Metastatic Uvea Melanoma
100%
Nivolumab
100%
Overall Survival
60%
Immunotherapy
40%
Adverse Event
40%
Progression Free Survival
40%
Systemic Therapy
20%
Maintenance Therapy
20%
Uvea Melanoma
20%
Pharmacology, Toxicology and Pharmaceutical Science
Ipilimumab
100%
Metastatic Uvea Melanoma
100%
Nivolumab
100%
Overall Survival
60%
Immunotherapy
40%
Adverse Event
40%
Progression Free Survival
40%
Uvea Melanoma
20%